Month: September 2020

IMPORTANT NOTICEBy reading the following communication, you agree to be bound by the following limitations and qualifications:This communication is for informational purposes only and is not intended to and does not constitute an offer or invitation to exchange or sell or solicitation of an offer to subscribe for or buy, or an invitation to exchange, purchase or subscribe for, any securities, any part of the business or assets described herein, or any other interests or the solicitation of any vote or approval in any jurisdiction in connection with the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. This communication should not be construed in any manner as a recommendation to any reader of this document.This communication is not...

MONTREAL, Sept. 17, 2020 (GLOBE NEWSWIRE) — Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”) is pleased to announce that its wholly-owned subsidiary in the US, BGX E-Health LLC ( “BGX”), has secured a USD$20 Million contract to supply critical PPE to the Canadian Health Care Market with deliveries starting the week of September 20th and ending by the first week of October 2020.Compared to revenues recorded during the fiscal year ended June 30, 2019, this initial contract is expected to increase forecasted yearly revenues for the year ending June 30, 2021 by an estimated 660%, from CAD$4.05M in 2019 to a forecasted CAD$30M for 2021.INITIAL CONTRACT TO SUPPLY PPE FOR CRITICAL NEEDS IN CANADAThe COVID-19 global pandemic has created significant gaps in the supply of PPE and the...

DealerMine CRM, Autovance and Quorum DMS will have staffed booths in the virtual exhibit hallAutovance’s digital retailing will be showcased in the event’s demo theatreCALGARY, Alberta, Sept. 17, 2020 (GLOBE NEWSWIRE) — Quorum Information Technologies Inc. (TSX Venture: QIS) (“Quorum” or the “Corporation”), announced today their sponsorship of the Trillium Auto Dealers Association’s (TADA) first virtual event, the Auto Dealers Innovation Series & Expo (ADIS), to occur next Thursday, September 24th.The event will include industry speakers, unique prize and networking opportunities, over 20 exhibitors and a demo theatre that will showcase vendors presenting the latest and greatest tools and technologies transforming the automotive retail industry. Dealers can attend from the comfort of their own desks.The...

VANCOUVER, British Columbia, Sept. 17, 2020 (GLOBE NEWSWIRE) — Trevali Mining Corporation (“Trevali” or the “Company”) (TSX: TV, BVL: TV; OTCQX: TREVF, Frankfurt: 4TI) announced the voting results from its Annual General Meeting of Shareholders (the “Meeting”) held on September 16, 2020. Shareholders voted in favour of all items of business before the Meeting as follows:Detailed voting results for the Meeting are available on SEDAR at www.sedar.com.About Trevali Mining CorporationTrevali is a global base-metals mining company, headquartered in Vancouver, Canada. The bulk of Trevali’s revenue is generated from base-metals mining at its three operational assets: the 90%-owned Perkoa Mine in Burkina Faso, the 90%-owned Rosh Pinah Mine in Namibia, and the wholly-owned Santander Mine in Peru. In addition, Trevali owns the Caribou Mine,...

DEVON, Pa., Sept. 17, 2020 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration has granted orphan drug designation for cannabidiol (CBD) for use in treating 22q11.2 deletion syndrome (22q). 22q is a rare midline condition featuring physical abnormalities and debilitating neuropsychiatric and behavioral symptoms including anxiety, withdrawn behavior, and social interaction problems.“Zynerba is committed to developing Zygel™ CBD gel in certain rare and near-rare conditions, including 22q, for which there is an urgent need for new, innovative therapeutics,” said Armando Anido, Chairman and Chief Executive Officer of Zynerba. “We...

– Study Met Primary Endpoint of Reduction of Time to Recovery– Additional Analyses Ongoing to Understand Other Clinical Outcome Data– Lilly’s Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Baricitinib ContinuesTORONTO, Sept. 17, 2020 (GLOBE NEWSWIRE) — On Monday, September 14th, Eli Lilly and Company and Incyte announced initial data emerging from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). ACTT-2 included more than 1,000 patients and began on May 8 to assess the efficacy and safety of a 4-mg dose of baricitinib plus remdesivir versus remdesivir in hospitalized patients with COVID-19.Baricitinib in combination with remdesivir met the primary endpoint of reduction of...

– L’étude a satisfait au critère d’évaluation principal, soit la réduction du temps de guérison– Des analyses supplémentaires sont en cours dans le but de comprendre la portée d’autres données sur les résultats cliniques– Lilly poursuit son étude de phase III à répartition aléatoire, à double insu et contrôlée par placebo sur le baricitinibTORONTO, 17 sept. 2020 (GLOBE NEWSWIRE) — Le lundi 14 septembre, Eli Lilly and Company et Incyte ont annoncé le dévoilement des premières données recueillies dans le cadre de l’étude sur le traitement adaptatif de la COVID-19 (ACTT-2) commanditée par le National Institute of Allergy and Infectious Diseases (NIAID), lequel fait partie des National Institutes of Health (NIH). L’ACTT-2, une étude portant sur plus de 1 000 patients, a commencé le 8 mai à évaluer l’efficacité et l’innocuité d’une dose...

LEXINGTON, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) — Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. David O’Malley, expert in gynecologic oncology, and members of Agenus’ management team will participate in a webcast hosted by Dr. Matt Phipps of William Blair on Monday September 21, 2020 at 2:30 p.m. ET.Dr. David O’Malley will review data of balstilimab as a monotherapy and in combination with zalifrelimab presented at ESMO from the largest clinical trials of IO therapies in refractory cervical cancer, and he will discuss the potential of this proprietary combination.  Members of the Agenus management team will be available to discuss the next steps...

ATCHISON, Kan., Sept. 17, 2020 (GLOBE NEWSWIRE) — Sarah Corwin, PhD, RD, has been named Principal Scientist for MGP Ingredients (Nasdaq: MGPI), a leading provider of specialty wheat proteins and starches. A PhD graduate in Food Science at Purdue University, Corwin completed her doctoral dissertation on slow-digesting carbohydrates, which will help support MGP’s research into the physiological benefits of dietary fiber in humans.At Purdue, Corwin managed the Carbohydrate Chemistry Laboratory and participated in numerous professional development activities provided by food and baking industry organizations, including the American Society of Baking (ASB) product development committee and as a volunteer with the Institute of Food Technologists (IFT) Carbohydrate Division Leadership. She also was an officer of The Cereals and Grains...

Simply Green’s Offer was by far the highest bid in a comprehensive strategic review processCash Offer is at a premium of 93% to the 90-day VWAP on the TSX-V for the period ending August 21, 2020TORONTO, Sept. 17, 2020 (GLOBE NEWSWIRE) — Dealnet Capital Corp. (“Dealnet” or the “Company“) (TSX VENTURE: DLS) reminds shareholders to tender their Dealnet common shares (the “Common Shares”) by October 14, 2020 to the premium cash offer of $0.16 per Common Share (the “Offer”) from Simply Group Acquisition Corp. (“Simply Green”) which commenced on September 9, 2020 through the mailing of a take-over bid circular to Dealnet shareholders.The Offer represents a premium of 33% to the closing price of the Common Shares on the TSX Venture Exchange (the “TSX-V”) on August 21, 2020 (the last trading day prior to the announcement...